Table of Contents Author Guidelines Submit a Manuscript
Erratum

An erratum for this article has been published. To view the erratum, please click here.

Dermatology Research and Practice
Volume 2018, Article ID 1284687, 5 pages
https://doi.org/10.1155/2018/1284687
Research Article

From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution

Scleroderma Unit, Chair of Rheumatology, University of Modena and Reggio Emilia, Modena, Italy

Correspondence should be addressed to Giuggioli Dilia; moc.liamtoh@iloigguigailid

Received 9 October 2017; Revised 6 December 2017; Accepted 28 December 2017; Published 30 January 2018

Academic Editor: Jag Bhawan

Copyright © 2018 Giuggioli Dilia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Systemic sclerosis (SSc) and localized scleroderma (LoS) are two different diseases that may share some features. We evaluated the relationship between SSc and LoS in our case series of SSc patients. Methods. We analysed the clinical records of 330 SSc patients, in order to find the eventual occurrence of both the two diseases. Results. Eight (2.4%) female patients presented both the two diagnoses in their clinical histories. Six developed LoS prior to SSc; in 4/6 cases, the presence of autoantibodies was observed before SSc diagnosis. Overall, the median time interval between LoS and SSc diagnosis was 18 (range 0–156) months. Conclusions. LoS and SSc are two distinct clinical entities that may coexist. Moreover, as anecdotally reported in pediatric populations, we suggested the possible development of SSc in adult patients with LoS, particularly in presence of Raynaud’s phenomenon or antinuclear antibodies before the SSc onset.